We are committed to improving patient outcomes with innovative diagnostic solutions for acute care that allow the diagnosis, outcome prediction, and monitoring of patients with acute medical conditions.
SphingoTec is a privately held company with its headquarters in Hennigsdorf near Berlin and with a wholly-owned subsidiary in San Diego, USA. With a long history of biomarker discovery, development, and validation, SphingoTec develops and markets innovative in vitro diagnostics solutions for its respective novel and proprietary blood-based protein biomarkers.
Our aspiration is to effectively translate scientific advancements into routine clinical practice. We develop biomarkers addressing diagnostically underserved critical care conditions such as sepsis, acute heart failure, acute kidney injury, and cardiogenic shock. On the Nexus IB10 point-of-care analyzer, clinicians can deploy a wide range of commonly used parameters in acute and critical care settings, making the analyzer a useful addition to intensive care units (ICU), and emergency departments (ED), and other near-patient settings.